Peer Exchange

The Pharmacy Times® Peer Exchange series is built around video panel discussions featuring some of the most recognizable names in pharmaceuticals. Each program focuses on a specific disease, condition, or therapy, and boasts energetic, moderated conversation on a variety of subjects and questions pertaining to the topic at hand.

What can we help you find?
Specialty Pharmacy Program
Annette Hood, PharmD, BCACP, discusses the role of special pharmacy programs to manage the administration of oral chemotherapy and PARP inhibitors, and emphasizes the impact medication assistance technicians have on mitigating treatment costs for patients.
VELIA Regimen
Expert oncologists discuss the VELIA study and the new frontline PARP inhibitor treatment veliparib.
ovarian cancer
A discussion of the PAOLO-1 trial regimen and the rationale behind combining olaparib and bevacizumab as post-chemotherapy maintenance.
Ovarian Cancer PRIMA
Maurie Markman, MD, leads a discussion on the design and results of the PRIMA trial, and how it has impacted practice.
constipation
Expert panelists conclude their discussion with parting advice on the management of opioid-induced constipation.
Key opinion leaders discuss the importance of HRD testing, with special consideration of tissue testing versus somatic testing.
Unmet Needs
Turning toward the future management of opioid-induced constipation, the panel defined unmet needs and potential evolutions in care.
Ovarian Cancer 6
A discussion on how to bring awareness to clinicians that are not aware of the role of an oncology pharmacist. 
Financial Considerations & Logistics of Therapy
Comprehensive insight regarding the cost and timing of peripherally acting mu-opioid receptor antagonist therapy in opioid-induced constipation.
Role of Oncology Pharmacists
Annette Hood, PharmD, BCACP, leads a discussion on the role of oncology pharmacists in supporting oncologists to determine the appropriate treatment plan for individuals with ovarian cancer.
Selecting a Specific PAMORA
Given the 3 available peripherally acting mu-opioid receptor antagonists for opioid-induced constipation, experts consider when to use a specific agent.
PAMORAs in OIC
Considerations for the safety/efficacy profile of peripherally acting mu-opioid receptor antagonists, particularly given their administration route.